Notably, targeted inhibition of the PD-L1-PI3K-AKT-mTOR signaling axis in AM patient-derived organoids significantly attenuated tumor growth, indicating the therapeutic potential of PD-L1 blockade as a novel and promising approach for the treatment of AM. The gene discussed is AKT1; the disease is acute myeloblastic leukemia with maturation.